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Challenges in 
interpreting SARS-
CoV-2 serological results 
in African countries
A diagnosis of COVID-19 is based on 
a positive PCR test for SARS-CoV-2. 
Over the past year, PCR testing 
capacity has varied globally due to 
the availability of tests, and testing 
strategies have targeted mainly 
symptomatic individuals. Therefore, 
the spread of the virus is probably 
wider than the numbers reported 
by official surveillance systems that 
are based on PCR results. Serology 
tests detect antibodies against SARS-
CoV-2, which start being measurable 
around 1–2 weeks after infection. 
They are used in seroprevalence 
studies to estimate the proportion of 
people in a population that has been 
infected, including asymptomatic 
infection. These studies are of 
particular importance in African 
countries, where reported testing and 
incidence are among the lowest in the 
world.
We did a cross-sectional serological 
survey of staff working in health-
care facilities in Kinshasa, the capital 
of the Democratic Republic of the 
Congo, where the first COVID-19 case 
was reported on March 10, 2020, in 
a traveller returning from France. We 
preselected five health zones across 
the city, from which we included one 
hospital, two health-care centres, 
and one COVID-19 response team. 
Within each facility, health-care 
workers and other service staff from 
different departments were randomly 
selected. Those who provided written 
consent to participate were enrolled 
in the study and a blood sample was 
taken, which was further analysed in 
the virology laboratory of the Institut 
National de la Recherche Biomédicale 
in Kinshasa. The study was approved 
by ethics committees in Belgium 
(number B3002020000144) and the 
Democratic Republic of the Congo 
(189/CNES/BN/PMMF/2020).
Between July 17 and Aug 13, 2020, 
562 blood samples were collected 
from 562 participants and five 
different SARS-CoV-2 serology tests 
were done on each sample: two in-
house Luminex IgG based assays using 
recombinant nucleocapsid and spike 
protein 1, and three commercial assays 
targeting the receptor binding domain 
on the spike protein, all validated by 
the manufacturers with serum samples 
from Europe. These three commercial 
assays were the EUROIMMUN 
IgG ELISA (EUROIMMUN, Lübeck, 
Germany)—a widely used assay in 
Europe, with sensitivity of 94·6% and 
specificity of 99·8%—and Quickzen 
IgG and IgM (Zentech, Belgium), a 
lateral flow test that detects IgG and 
IgM antibodies on a single device with 
a specificity of 100% and sensitivity 
of 68·8% for IgM and 49·2% for IgG.1 
The blood samples were also tested for 
malaria with microscopy at the same 
facility.
The median age of participants was 
42 years; 242 (43%) of 562 participants 
were male and 320 (57%) were female. 
27 study participants declared having 
previously had a SARS-CoV-2 PCR test 
between March and July, of whom 
eight (30%) of 27 reported a positive 
result (1% of the total population).
202 samples (36%) were sero-
positive using the EUROIMMUN IgG, 
171 (30%) using the Quickzen IgM 
and 72 (13%) using the Quickzen IgG. 
Only 46 (8%) of 562 samples were 
positive by all three tests. 89 (16%) 
samples were positive for malaria by 
microscopy. Two of eight participants 
who had previously tested positive by 
SARS-CoV-2 PCR were seronegative by 
all three commercial serology tests.
The Kappa coefficient, used to 
measure agreement between tests,2 
was 0·3 for the EUROIMMUN IgG assay 
and the Quickzen IgG assay, which 
is considered a minimal agreement. 
Because specificity for both tests is 
nearly 100%, but sensitivity is very 
different, we assessed whether all 
samples that were positive with 
the Quickzen IgG assay would be 
confirmed as positive with the 
EUROIMMUN IgG. Only 59 (82%) of 
72 samples that were positive with the 
Quickzen IgG assay were also positive 
with the EUROIMMUN IgG assay.
Depending on the commercial 
assay used, seropositivity in health-
care staff in our study varied 
between 13% and 36%, which is 
relatively high considering the low 
number of symptomatic and severe 
cases reported in Kinshasa by the 
end of the study period. In other 
African countries, SARS-CoV-2 sero-
prevalence has been estimated at 
45·1% in frontline health-care workers 
in Nigeria (Elabscience ELISA IgG),3 
40% in women attending antenatal 
clinics and people living with HIV in 
South Africa (Roche ECLIA IgG and 
IgM),4 12·3% in health-care workers 
in Malawi (Omega ELISA spike protein 
and nucleocapsid protein,5 5·6% in 
blood donors in Kenya (in-house ELISA 
IgG),6 and 3% in the general population 
in Ethiopia (Abbott CMIA IgG).7 
Although these studies were done in 
different settings and using different 
serological tests, all of them tend to 
give a higher seroprevalence than 
expected on the basis of surveillance 
data of confirmed cases in the study 
period. Given our observations, part 
of this discrepancy could be due to the 
assays used.
One explanatory hypothesis for 
the higher than expected rate of 
seropositivity could be because of 
cross-reaction of the tests with other 
circulating viruses or parasites in 
the African subcontinent that could 
lower their specificity. The presence 
of pre-existing antibodies recognising 
SARS-CoV-2 in uninfected individuals 
due to seasonal coronaviruses was 
identified by Ng and colleagues,8 
whereas Tso and colleagues9 showed 
that pre-pandemic samples from 
sub-Saharan Africa had higher cross-
reactivity against SARS-CoV-2 than 
those from the USA. However, these 
observations need to be confirmed in 
larger sample sizes to assess whether 
prevalence of pre-existing antibodies 
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the serological profile dynamics. It will 
be necessary to develop standardised 
testing strategies, as was done in 
the past for serological diagnosis of 
HIV, and assess assays for sensitivity 
and specificity on reference panels 
that include samples from different 
geographical areas, including Africa.
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are consistently higher in African 
countries. Cross-reactivity between 
SARS-CoV-2 and acute malaria 
infection was observed in a study in 
Benin by Yadouleton and colleagues.10 
Our data do not show any correlation 
between participants who tested 
positive for malaria and those testing 
positive with any of the commercial 
SARS-CoV-2 serological tests.
Notably, SARS-CoV-2 emerged only 
1 year ago and antibody response 
according to severity of infection and 
the duration of antibody persistence 
are not yet completely understood. 
However, sensitivities and specificities 
of serological assays can vary across 
populations, as shown in the early 
1990s with HIV serological tests, 
for which lower specificity in serum 
samples from African individuals 
was observed than in samples from 
European individuals.11
The potential lower specificity of 
SARS-CoV-2 commercial tests in 
African countries, together with the 
low reported prevalence of clinical 
cases, makes the interpretation of 
population surveys in this setting 
difficult. The seroprevalence results 
could be misleading and even report 
more false-positive cases than true-
positive cases.12
On the basis of the low agreement 
between test results of our study and 
the available literature, we would 
like to warn the research community 
and policy makers to interpret with 
caution the results of seroprevalence 
studies done in African countries with 
commercial tests validated in Europe, 
the USA, or Asia. To establish whether 
these high seroprevalences are a sign of 
serious under-reporting of COVID-19 
cases, a milder COVID-19 clinical 
presentation, or a cross-reaction 
with other circulating pathogens, we 
recommend in this context the use 
of a combination of serological tests, 
targeting two or more independent 
antigens, adjusting the cutoff values 
due to the overall higher background 
noise, or repeated serosurveys of the 
same population to better understand 
